BioCina

BioCina Pty Ltd. is a multi-product biologics contract development and manufacturing organization (CDMO) specializing in the development and cGMP manufacturing of microbial biopharmaceuticals, including proteins, pDNA, mRNA, vaccines, and biosimilars, from early-stage development through to commercialization. The BioCina Adelaide facility, formerly the Pfizer/Hospira plant, spans nearly 60,000 square feet dedicated to GMP production, process development, warehousing, and management. The team has over 35 years of experience and extensive capabilities in microbial process development and manufacturing, with expertise ranging from early-stage process development to commercial manufacturing. BioCina boasts an enviable track record, with its manufactured biologics having received commercial approval from the U.S. FDA, EMA, and Health Canada, including the production of active pharmaceutical ingredients for all clinical trial phases. BioCina holds a GMP manufacturing license from Australia’s Therapeutic Goods Administration (TGA) and is the only GMP facility in Australia to have successfully passed a U.S. FDA inspection. BioCina is a portfolio company of the Bridgewest Group.